Receiving a Thai FDA marketing authorization is not the end of the regulatory work. The MA runs for 7 years and must be actively managed: product changes require variation submissions before implementation, the import license renews every year, and the MA itself must be renewed within a defined window before it expires. Products that drift from their approved specifications without a variation on file are at regulatory risk.
When Thai FDA grants a marketing authorization, it approves a specific product at a specific manufacturer, in a specific dosage form and strength, with specific labeling, specifications, and manufacturing process. Any change to these approved parameters, whether initiated by the manufacturer or required by circumstances, must be reported to Thai FDA and, depending on the nature of the change, approved before implementation.
Foreign manufacturers who manage post-approval compliance in other markets sometimes assume the process in Thailand will be similar to their home regulatory system. The specific change classification criteria, submission formats, and approval timelines differ. Changes implemented before the required Thai FDA approval are non-compliant regardless of whether the same change was previously approved in another market.
The Local Authorized Representative (LAR), as the marketing authorization holder on record, bears legal responsibility for ensuring that all post-approval obligations are met and that Thai FDA is notified of changes within the required timeframes.
Under the 2019 amendment to the Drug Act (B.E. 2562, 2019), all new marketing authorizations are valid for 7 years from the date of issuance. For MAs issued before the 2019 amendment, Thai FDA introduced a staggered expiry schedule: MAs issued before January 1, 1997 expired on October 13, 2024; MAs issued between January 1, 1997 and December 31, 2007 expire on October 13, 2026; MAs issued between January 1, 2008 and October 13, 2019 expire on October 13, 2028.
The renewal application must be submitted to Thai FDA within the 1-year window before the MA's expiration date. Submission outside this window, either too early or too late, will not be accepted. Thai FDA requires that the renewal application be submitted online through its electronic system. Paper submissions are not accepted for MA renewals.
Thai FDA will grant a renewal if the product's efficacy and safety data are up to date and consistent with current academic and regulatory standards, and the product's specifications and analytical methods comply with the applicable pharmacopeias. The LAR must certify that the product information reflects the current approved label and that no unapproved changes have been made since the MA was issued or last renewed. A complete and accurate pharmacovigilance summary may also be required.
An MA that lapses cannot be commercially distributed in Thailand. Products already on the Thai market under a lapsed MA must be withdrawn from sale. Reinstating a lapsed MA requires a new registration application, not a renewal: the full registration process, including dossier submission and review, applies. This is not a recoverable situation on a short timeline.
A variation is any post-approval change to the terms of a marketing authorization. Thailand follows the ASEAN Variation Guideline (AVG) framework for classifying and processing variations. Variations are classified as either major or minor based on their potential impact on the quality, safety, and efficacy of the product. The classification determines the documentation required and whether prior Thai FDA approval must be obtained before the change is implemented.
Changes that could significantly affect the quality, safety, or efficacy of the product. Examples include: changes to the active pharmaceutical ingredient manufacturer or manufacturing process; changes to the drug product manufacturing site; significant changes to the approved specifications; addition of a new indication; changes to the approved dosage or administration instructions; and changes to contraindications or warnings based on new safety data. Major variations require Thai FDA approval before the change can be implemented commercially. The applicant must not introduce the change until the variation is approved.
Changes with minimal potential to affect the product's quality, safety, or efficacy. Examples include: minor labeling updates such as changes to the LAR's contact information; changes to secondary packaging materials that do not affect product protection or storage; and administrative corrections to the registration file that do not affect the approved product. Minor variations may be submitted for notification rather than prior approval in some cases, but this depends on the specific change and Thai FDA's current guidance.
Implementing a major variation before Thai FDA approval is a compliance violation. The product bearing the unapproved change is considered to be non-conforming with its marketing authorization. Thai FDA may issue a warning, require market withdrawal of affected batches, or take enforcement action. The commercial pressure to implement a change quickly does not change the regulatory requirement to obtain approval first.
Changes to the overseas manufacturing site that fall below the threshold for a formal variation, such as minor equipment modifications or internal process improvements, may still require notification to Thai FDA and update of the GMP accreditation file. The boundary between a notifiable change and a variation requiring prior approval is not always obvious and should be assessed by a qualified regulatory specialist before the change is made.
The drug import license held by the Importer of Record (IOR) runs on an annual cycle, expiring on December 31 of each calendar year regardless of when it was originally issued. Unlike the marketing authorization, which runs for 7 years, the import license does not automatically continue into the following year. It must be renewed annually.
A product whose MA is current but whose import license has lapsed cannot legally be imported into Thailand. Commercial shipments held at Thai Customs because the IOR's import license expired are not released until the license is reinstated. The renewal application should be submitted well before the December 31 deadline to avoid any gap in import authority during the renewal processing period.
For manufacturers with multiple products and multiple import permit events throughout the year, the annual import license renewal is a fixed compliance deadline that must be tracked and managed as a priority, not as a routine administrative task at year-end.
A foreign manufacturer with a registered product in Thailand is simultaneously managing at least 3 regulatory timelines that run on different cycles and carry different consequences if they lapse:
The MA must be renewed within the 1-year window before expiry. Renewal preparation, including updating the dossier to reflect any changes made since registration and compiling the pharmacovigilance summary, should begin no later than 18 months before the MA expiry date to allow time for documentation review and electronic submission.
The GMP clearance issued by Thai FDA tracks the validity of the home country GMP certificate, typically 3 years. Renewal requires a fresh documentation package that reflects the site's current inspection status and GMP certificate. This cycle does not align with the MA renewal cycle and must be tracked separately.
The IOR's import license expires on December 31 each year. Annual renewal is a fixed, non-negotiable deadline. For manufacturers who import multiple times per year, a lapsed import license stops all shipments immediately.
None of these cycles align with each other by default. A compliance calendar that tracks all three, along with any outstanding variation submissions, is the minimum management tool required to maintain uninterrupted market access in Thailand.
We manage the full post-approval lifecycle for the products we register. That means we track MA expiry dates, GMP accreditation cycles, and annual import license renewals in parallel, and we initiate renewal processes on a schedule that gives Thai FDA adequate time to process without creating gaps in market access.
When a manufacturer needs to make a change to an approved product, we assess the change against Thai FDA's variation classification criteria, determine whether prior approval is required, prepare the variation submission, and manage the correspondence with Thai FDA through to approval. We do not advise clients to implement changes before approval is received.
For manufacturers who registered their products before engaging us, we conduct a compliance audit of the existing marketing authorization: we verify that all post-registration changes have been properly captured as variations, that the current label and approved specifications are aligned, and that no gaps in the GMP or import license cycle have occurred. We tell clients what we find, not what they want to hear.